Dr. James N. Mason, D.O.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Oklahoma State University College of Osteopathic Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 229
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Oklahoma State University College of Osteopathic Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license Q8954 (first issued 2016; delinquent - incomplete registration)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor Scott & White Medical Center - Temple Temple, TX
- Intermountain Medical Center Murray, UT
- Intermountain Health Mckay-Dee Hospital Ogden, UT
- Intermountain Health Layton Hospital Layton, UT
Medical groups
- Ihc Health Services Inc (3,960 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 229
- Services billed
- 799
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 264 | 153 |
| Established patient office or other outpatient visit, 40-54 minutes | 187 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 107 | 26 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 39 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 31 |
| Hospital discharge day management, more than 30 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Ogden, UT | 135 |
| Hydroxyurea Other prescribers in Ogden, UT | 97 |
| Eliquis (apixaban) Other prescribers in Ogden, UT | 79 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Ogden, UT | 49 |
| Imatinib Mesylate | 38 |
| Calquence (acalabrutinib maleate) | 38 |
| Deferasirox | 37 |
| Acyclovir Other prescribers in Ogden, UT | 35 |
| Pomalyst (pomalidomide) | 32 |
| Dexamethasone Other prescribers in Ogden, UT | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $200 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $106 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $77.63 |
| Regeneron Healthcare Solutions, Inc. | $16.79 |
| Food and Beverage | $200 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $10,533 in research payments for these studies, mostly to the institutions running them.
- A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
Taiho Oncology, Inc. - ASTX727-07
Taiho Oncology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.